NCT06799637

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Efficacy of XNW28012 in Subjects With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 350 (estimated)
• Sponsor: Evopoint Biosciences Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies. The study consists of two parts: a dose escalation part and a dose expansion part.

Conditions

• Advanced Solid Tumors
• Pancreatic Carcinoma
• Ovarian Cancer
• Cervical Cancers

Interventions

Type	Name	Description
DRUG	XNW28012	Eligible subjects will receive XNW28012 every 3 weeks (Q3W) until intolerant toxicity, progression of disease with no clinical benefit, or withdrawal of informed consent.

Timeline

• Start date: 2023-12-01
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2025-01-29
• Last updated: 2026-04-15

Locations

24 sites across 1 country: China